You are here:
Home
:
PCU Think Tank 1 | 2006
:
Audio Program Guide
:
PCU Think Tank 1 | 2006 Audio
Go to Section 1
Go to Section 2
Go to Section 3
Go to Section 4
Go to Section 5
Go to Section 6
Go to Section 7
Go to Section 8
Go to Section 9
To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
Section 1:
Salvage Cryotherapy
Click here to download the entire segment
Track 1
Introduction
Track 2
Cryotherapy for the treatment of local recurrence following radiation therapy
Track 3
Advances in cryotherapy techniques
Track 4
Lack of standardization of cryotherapy techniques
Track 5
Randomized trial comparing cryotherapy to radiation therapy for locally advanced disease
Track 6
Strategies for accruing patients to clinical trials in Canada
Track 7
Obstacles to physician support of clinical trials
Track 8
Impact of physician education on participation in clinical trials
Section 2:
PSA as a Prognostic Indicator
Click here to download the entire segment
Track 1
Introduction
Track 2
Natural history of prostate cancer
Track 3
Risk factors for prostate cancer mortality
Track 4
Predictive value of PSA doubling time versus other variables
Track 5
Changes in PSA doubling time as the disease progresses
Track 6
Determination of PSA doubling time
Track 7
Definition of PSA recurrence
Section 3:
Treatment for Patients with PSA-Only Relapse
Click here to download the entire segment
Track 1
Introduction
Track 2
Selection of patients to treat for PSA-only relapse
Track 3
Treatment alternatives for patients with PSA-only relapse
Track 4
Determination of appropriate endpoints for clinical trials for PSA-only recurrence
Track 5
Proposed clinical trial of androgen deprivation therapy with or without docetaxel for PSA-only recurrence
Track 6
Chemotherapy for the treatment of PSA-only disease in clinical practice
Track 7
Relationship between PSA doubling time and clinical disease progression
Track 8
Calculation of PSA doubling time
Section 4:
Combined Androgen Blockade
Click here to download the entire segment
Track 1
Introduction
Track 2
Evolution of maximum androgen blockade (MAB) therapy
Track 3
Ketoconazole as second-line hormonal therapy for prostate cancer
Track 4
Use of MAB in clinical practice
Track 5
Benefit of MAB in the treatment of metastatic disease
Track 6
Clinical trials evaluating MAB
Section 5:
Intermittent Androgen Deprivation
Click here to download the entire segment
Track 1
Introduction
Track 2
Evolution of clinical research on intermittent androgen therapy
Track 3
Intermittent versus continuous androgen therapy
Track 4
Potential role of 5-alpha-reductase inhibitors in managing prostate cancer
Track 5
Mechanism of action of 5-alpha-reductase inhibitors
Track 6
Selection of patients for intermittent androgen therapy
Track 7
Survival rates with combined versus continuous and early versus delayed therapy
Section 6:
Adjuvant and Neoadjuvant Systemic Therapies
Click here to download the entire segment
Track 1
Introduction
Track 2
Combining hormonal therapy with high-dose radiation therapy
Track 3
Clinical trial of neoadjuvant docetaxel
Track 4
Radiation therapy with hormonal therapy for the treatment of locally advanced or high-risk disease
Track 5
Adjuvant therapy for patients with high-risk disease after radical prostatectomy
Track 6
Role of hormonal therapy: Cure or palliation
Track 7
Cardiovascular morbidity in patients receiving androgen deprivation therapy
Section 7:
Radiation Therapy for High-Risk Disease
Click here to download the entire segment
Track 1
Introduction
Track 2
SWOG-S8794: Phase III trial comparing adjuvant radiation therapy to no adjuvant therapy following radical prostatectomy
Track 3
Selection of patients for postprostatectomy radiation therapy based on risk
Track 4
Efficacy of adjuvant versus salvage radiation therapy
Section 8:
Clinical Trials of Adjuvant Chemotherapy for High-Risk Disease
Click here to download the entire segment
Track 1
Introduction
Track 2
Clinical trials evaluating adjuvant chemotherapy for patients at high risk
Track 3
Importance of completing clinical trials of adjuvant chemotherapy in prostate cancer
Track 4
Redefining high-risk versus intermediate-risk cases
Track 5
TAX-3501: Immediate adjuvant leuprolide with or without docetaxel versus deferred therapy followed by the same therapeutic options in patients at high risk of relapse postprostatectomy
Section 9:
Treatment of Patients with Metastatic Disease
Click here to download the entire segment
Track 1
Introduction
Track 2
Efficacy and tolerability of docetaxel-based chemotherapy in metastatic disease
Track 3
Ongoing trials evaluating docetaxel in combination with novel agents for hormone-refractory prostate cancer
Track 4
Improved quality of life with docetaxel-based chemotherapy in the treatment of metastatic disease
Track 5
Effects of long-term androgen deprivation on bone density
Track 6
Benefit of vitamin D and calcium for patients receiving androgen deprivation therapy
Track 7
Monitoring bone mineral density in patients receiving androgen deprivation therapy
Terms of Use and General Disclaimer
Copyright © Research To Practice, 2006. All Rights Reserved.